Trends in resource utilization for Parkinson's disease in Germany

Journal of the Neurological Sciences

Volumn 294, Issue 1-2, 2010, Pages 18-22

  Winter, Yaroslav ^a   Balzer Geldsetzer, Monika ^a   von Campenhausen, Sonja ^a   Spottke, Annika ^b   Eggert, Karla ^a   Oertel, Wolfgang H ^a   Dodel, Richard ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Cost of illness; Costs; Parkinson's disease; Resource utilization

Indexed keywords

ANTIPARKINSON AGENT; DOPAMINE RECEPTOR STIMULATING AGENT;

ADULT; AGED; ARTICLE; CLINICAL EVALUATION; COHORT ANALYSIS; COST OF ILLNESS; DRUG COST; ECONOMIC EVALUATION; FEMALE; GENERAL PRACTITIONER; GERMANY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOME CARE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROLOGY; OUTPATIENT CARE; PARKINSON DISEASE; PATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL; STRUCTURED INTERVIEW; AGE; CLINICAL TRIAL; COMPLICATION; DISEASE COURSE; ECONOMICS; HEALTH CARE PLANNING; MEDICAL RECORD; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; SOCIOECONOMICS; TRENDS; UTILIZATION;

AGE FACTORS; ANTIPARKINSON AGENTS; COHORT STUDIES; DISEASE PROGRESSION; DOPAMINE AGONISTS; DRUG COSTS; FEMALE; GERMANY; HEALTH CARE COSTS; HEALTH RESOURCES; HOSPITALIZATION; HUMANS; MALE; MEDICAL RECORDS; MULTIVARIATE ANALYSIS; PARKINSON DISEASE; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; SOCIOECONOMIC FACTORS;

EID: 77953322695     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2010.04.011     Document Type: Article

References (40)

1. Dorsey E.R., Constantinescu R., Thompson J.P., Biglan K.M., Holloway R.G., Kieburtz K., et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68 5 (2007) 384-386
2. Alves G., Forsaa E.B., Pedersen K.F., Dreetz Gjerstad M., and Larsen J.P. Epidemiology of Parkinson's disease. J Neurol 255 Suppl 5 (Sep 2008) 18-32
3. Winter Y., Bezdolnyy Y., Katunina E., Avakjan G., Reese J.P., Klotsche J., et al. Incidence of Parkinson's disease and atypical Parkinsonism: Russian population-based study. Mov Disord 25 3 (Jan 27 2010) 349-356
4. de Lau L.M., and Breteler M.M. Epidemiology of Parkinson's disease. Lancet Neurol 5 6 (Jun 2006) 525-535
5. Winter Y., von Campenhausen S., Popov G., Reese J.P., Klotsche J., Botzel K., et al. Costs of illness in a Russian cohort of patients with Parkinson's disease. Pharmacoeconomics 27 7 (Jul 1 2009) 571-584
6. Winter Y., von Campenhausen S., Brozova H., Skoupa J., Reese J.P., Botzel K., et al. Costs of Parkinson's disease in Eastern Europe: a Czech cohort study. Parkinsonism Relat Disord 16 1 (Jan 2010) 51-56
7. von Campenhausen S., Winter Y., Gasser J., Seppi K., Reese J.P., Pfeiffer K.P., et al. Cost of illness and health services patterns in Morbus Parkinson in Austria. Wien Klin Wochenschr 121 17-18 (2009) 574-582
8. Findley L., Aujla M., Bain P.G., Baker M., Beech C., Bowman C., et al. Direct economic impact of Parkinson's disease: a research survey in the United Kingdom. Mov Disord 18 (2003) 1139-1145
9. Whetten-Goldstein K., Sloan F., Kulas E., Cutson T., and Schenkman M. The burden of Parkinson's disease on society, family, and the individual. J Am Geriatr Soc 45 7 (1997) 844-849
10. LePen C., Wait S., Moutard-Martin F., Dujardin M., and Ziegler M. Cost of illness and disease severity in a cohort of French patients with Parkinson's disease. Pharmacoeconomics 16 (1999) 59-69
11. Muller T., Voss B., Hellwig K., Josef Stein F., Schulte T., and Przuntek H. Treatment benefit and daily drug costs associated with treating Parkinson's disease in a Parkinson's disease clinic. CNS Drugs 18 2 (2004) 105-111
12. Keller S., Kessler T., Meuser T., Fogel W., Bremen D., and Jost W.H. Analysis of direct costs in therapy of Parkinson disease. Nervenarzt 74 12 (2003) 1105-1109
13. Spottke A.E., Reuter M., Machat O., Bornschein B., von Campenhausen S., Berger K., et al. Cost of illness and its predictors for Parkinson's disease in Germany. Pharmacoeconomics 23 (2005) 817-836
14. Keranen T., Kaakkola S., and Sotaniemi K. Economic burden and quality of life impairment increase with severity of PD. Parkinsonism Relat Disord 9 (2003) 163-168
15. Hagell P., Nordling S., Reimer J., Grabowski M., and Persson U. Resource use and costs in a Swedish cohort of patients with Parkinson's disease. Mov Disord 17 (2002) 1213-1220
16. Haycock J. Idiopathic Parkinson's disease: the burden of illness [Dissertation]. York: University of York 1992
17. Noyes K., Liu H., Li Y., Holloway R., and Dick A.W. Economic burden associated with Parkinson's disease on elderly Medicare beneficiaries. Mov Disord 21 3 (2006) 362-372
18. Huse D.M., Schulman K., Orsini L., Castelli-Haley J., Kennedy S., and Lenhart G. Burden of illness in Parkinson's disease. Mov Disord 20 11 (2005) 1449-1454
19. Ragothaman M., Govindappa S.T., Rattihalli R., Subbakrishna D.K., and Muthane U.B. Direct costs of managing Parkinson's disease in India: concerns in a developing country. Mov Disord 21 10 (2006) 1755-1758
20. Gibb W.R.G. Accuracy in the clinical diagnosis of parkinsonian syndromes. Postgrad Med J 64 (1988) 345-512
21. German Diagnosis Related Groups. Available from: www.g-drg.de (assessed at 12.01.2009).
22. German official medical fee scale. Köln: Deutscher Arzteverlag, 2006.
23. The Federal Ministry for Health and Social Secure. www.bmg.bund.de (assessed at 08.03.2009).
24. The Federation of German Pharmaceutical Industry. Rote Liste. Weinheim: Rote Liste Verlag 2006.
25. The German Federal Ministry of Justice. www.bmj.bund.de (assessed at 20.02.2009).
26. The Federal Statistical Office Germany. Available from: http://www.destatis.de (assessed at 22.07.2009).
27. Barber J.A., and Thompson S.G. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med 19 (2000) 3219-3236
28. Efron B., and Tibshirani R.J. An introduction to the bootstrap (1993), Chapman and Hall, London
29. Harrell F.E. Regression modeling strategies (2001), Springer, New York
30. Lindgren P., von Campenhausen S., Spottke A.E., Siebert U., and Dodel R. Cost of Parkinson's disease in Europe. Eur J Neurol 12 Suppl 1 (2005) 68-73
31. Rubenstein L.M., Chrischilles E.A., and Voelker M.D. The impact of Parkinson's disease on health status, health expenditures, and productivity: estimates from the National Medical Expenditure Survey. Pharmacoeconomics 12 4 (1997) 486-498
32. Davis C., and Rhodes D.J. The impact of DRGs on the cost and quality of health care in the United States. Health Policy 9 2 (1988) 117-131
33. Muller T., V.B., Hellwig K., and Przuntek H. Treatment benefit correlates with increase of daily drug costs in Parkinson's disease clinics. Neurorehabilitation 18 3 (2003) 271-275
34. Muzerengi S., Contrafatto D., and Chaudhuri K.R. Non-motor symptoms: identification and management. Parkinsonism Relat Disord 13 3 (2007) 450-456
35. Wang G., Cheng Q., Zheng R., Tan Y.Y., Sun X.K., Zhou H.Y., et al. Economic burden of Parkinson's disease in a developing country: a retrospective cost analysis in Shanghai, China. Mov Disord 21 9 (2006) 1439-1443
36. MacMahon D.G., Findley L., Holmes J., and Pugner K. The true economic impact of Parkinson's disease: a research survey in the U.K. Mov Disord 15 3 (2000) 178-179
37. Epifanov Y., Dodel R., Haacke C., Schaeg M., Schoeffski O., Hennerici M., et al. Costs of acute stroke care on regular neurological wards: a comparison with stroke unit setting. Health Policy 81 2-3 (2007) 339-349
38. Jonsson B. Ten arguments for a societal perspective in the economic evaluation of medical innovations. Eur J Health Econ 10 4 (Oct 2009) 357-359
39. Koopmanschap M.A., Rutten F.F., van Ineveld B.M., and van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ 14 2 (1995) 171-189
40. von der Schulenburg J.-M., and Hoffmann C. Review of European guidelines for economic evaluation of medical technologies and pharmaceuticals. HEPAC 1 (2000) 2-8